Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

• DOI: 10.1038/leu.2008.214
• Publication Date: 2008-08-28T09:48:50Z
• Authors: J E Castro; J D Sandoval-Sus; J Bole; L Rassenti; T J Kipps
• Keywords: Adult; Male; Maximum Tolerated Dose; Remission Induction; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antineoplastic Agents; Middle Aged; Myeloablative Agonists; Antigens, CD20; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Disease-Free Survival; 3. Good health; Antibodies, Monoclonal, Murine-Derived; 03 medical and health sciences; 0302 clinical medicine; Drug Resistance, Neoplasm; Disease Progression; Humans; Drug Therapy, Combination; Female; Aged

We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days). All patients were refractory to fludarabine and 86% had high-risk disease by the modified Rai classification. In all, 79% of the patients had CLL cells that expressed ZAP-70 and three patients had poor prognostic cytogenetics. The overall response rate was 93% and the complete remission rate was 36%. The median time-to-progression was 15 months and the median time-to-next treatment was 22 months. Median survival has not been reached after a median follow up of 40 months. Four patients have died of progressive disease. Patients tolerated the treatment well and serious adverse events were rare. This allowed patients to receive all planned treatments on schedule with no dose modifications. All but one patient responded to treatment and the overall survival and time-to-progression were superior to those of other published salvage regimens.